Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 40.73 USD -6.13% Market Closed
Market Cap: 1.5B USD

Relative Value

The Relative Value of one GRAL stock under the Base Case scenario is 29.67 USD. Compared to the current market price of 40.73 USD, Grail Inc is Overvalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GRAL Relative Value
Base Case
29.67 USD
Overvaluation 27%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
6
vs Industry
46
Median 3Y
4.8
Median 5Y
4.8
Industry
7.5
Forward
10.2
vs History
vs Industry
Median 3Y
-0.3
Median 5Y
-0.3
Industry
23.6
Forward
-2.8
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-1.1
Industry
20.2
vs History
vs Industry
Median 3Y
-1
Median 5Y
-1
Industry
22.9
vs History
6
vs Industry
72
Median 3Y
0.2
Median 5Y
0.2
Industry
2.8
vs History
6
vs Industry
63
Median 3Y
0
Median 5Y
0
Industry
7.7
Forward
5.7
vs History
6
vs Industry
53
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
4.9
Forward
-2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
4.9
Forward
-1.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
4
vs History
6
vs Industry
69
Median 3Y
0
Median 5Y
0
Industry
5.1

Multiples Across Competitors

GRAL Competitors Multiples
Grail Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Grail Inc
NASDAQ:GRAL
1.5B USD 11 -0.8 -0.4 -0.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 905 135.8 -161 146.1 -195 682.7 -193 449.8
US
Abbvie Inc
NYSE:ABBV
339.9B USD 5.9 81.8 15.5 23
US
Amgen Inc
NASDAQ:AMGN
158.8B USD 4.7 26.8 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
136.5B USD 4.8 22.9 10 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.5B USD 10.9 -121.8 25.9 27.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 077.8 -530.2 -577.3 -561.9
AU
CSL Ltd
ASX:CSL
116.7B AUD 5 27.9 17.2 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.4B USD 4.4 13.7 12.2 13.7
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.4 -66.2 -59.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.3B USD 17.5 -152.2 -686.3 -343.9
P/S Multiple
Revenue Growth P/S to Growth
US
Grail Inc
NASDAQ:GRAL
Average P/S: 3 082 481.6
11
20%
0.5
FR
Pharnext SCA
OTC:PNEXF
33 905 135.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.9
10%
1.1
US
E
Epizyme Inc
F:EPE
2 077.8
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.4
4%
1.1
US
S
Seagen Inc
F:SGT
20
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.5
30%
0.6
P/E Multiple
Earnings Growth PEG
US
Grail Inc
NASDAQ:GRAL
Average P/E: 34.6
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 146.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.8
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.9
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -121.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.9
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
7%
2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -152.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Grail Inc
NASDAQ:GRAL
Average EV/EBITDA: 15.9
Negative Multiple: -0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 682.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -686.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Grail Inc
NASDAQ:GRAL
Average EV/EBIT: 20.5
Negative Multiple: -0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 449.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -343.9 N/A N/A